Carbon Dots as a Potential Therapeutic Agent for the Treatment of Cancer-Related Anemia

Adv Mater. 2022 May;34(19):e2200905. doi: 10.1002/adma.202200905. Epub 2022 Apr 9.

Abstract

Due to the adverse effects of erythropoietin (EPO) on cancer patient survival, it is necessary to develop new agents that can be used to efficiently manage and treat cancer-related anemia. In this study, novel distinctive carbon dots, J-CDs, derived from jujube are designed, synthesized, and characterized. Based on the obtained results, this material comprises sp2 and sp3 carbon atoms, as well as oxygen/nitrogen-based groups, and it specifically promotes the proliferation of erythroid cells by stimulating the self-renewal of erythroid progenitor cells in vitro and in vivo. Moreover, J-CDs have no discernible effects on tumor proliferation and metastasis, unlike EPO. Transcriptome profiling suggests that J-CDs upregulate the molecules involved in hypoxia response, and they also significantly increase the phosphorylation levels of STAT5, the major transducer of signals for erythroid progenitor cell proliferation. Overall, this study demonstrates that J-CDs effectively promote erythrocyte production without affecting tumor proliferation and metastasis; thus, they may be promising agents for the treatment of cancer-related anemia.

Keywords: cancer-related anemia; carbon dots; erythroid progenitor cells; erythropoiesis; self-renewal; tumor proliferation.

MeSH terms

  • Anemia* / drug therapy
  • Anemia* / pathology
  • Carbon / pharmacology
  • Carbon / therapeutic use
  • Erythroid Precursor Cells / pathology
  • Erythroid Precursor Cells / physiology
  • Erythropoiesis / physiology
  • Erythropoietin* / pharmacology
  • Erythropoietin* / therapeutic use
  • Humans
  • Neoplasms* / complications
  • Neoplasms* / drug therapy

Substances

  • Erythropoietin
  • Carbon